Cancer Chemoprevention Part 1: Retinoids and Garotenoids and Other Classic Antioxidants

ONCOLOGY

Volumn 12, Issue 11, 1998, Pages 1643-1658

  Singh, Diljeet K ^a   Lippman, Scott M ^b  

^a Department of Gynecologic Oncology ^*

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CAROTENOID; FINASTERIDE; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRASTERONE; RETINOIC ACID; RETINOID; SELENIUM; TAMOXIFEN CITRATE;

ANTIOXIDANT ACTIVITY; CANCER; CANCER INVASION; CANCER PREVENTION; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CAROTENOIDS; CLINICAL TRIALS; HUMANS; NEOPLASMS; RETINOIDS;

EID: 0031772908     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Lotan R: Retinoids in cancer chemoprevention. FASEB J 10:1031-1039, 1996.
2. Mavne ST, Lippman SM: Retinoids and carolenoids, in DeVila VT, Hellman S, Rosenberg SA (eds): Cancer Principles & Practice of Oncology, 5th ed, pp 585-599. Philadelphia, Lippincott-Raven, 1997.
3. Meyskens FL: Cancer prevention: Diet and risk reduction, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer Principles & Practice of Oncology, 5th ed, pp 573-579 Philadelphia, Lippincott-Raven, 1997.
4. Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs. Fed Proc 35:1332-1338, 1976.
5. Sporn MB: Chemoprevention of cancer. Lancer 342:1211-1213, 1993.
6. Bertram JS, Kolonel LN, Meyskens FL: Rationale and strategies for Chemoprevention of cancer in humans. Cancer Res 47:3012-3031, 1987.
7. Slaga TJ: Cellular and molecular mechanisms involved in multistage skin carcinogenesis. Carcinog Compr Surv 11:1-18, 1989.
8. DiGiovanni J: Inhibition of chemical carcinogenesis, in Cooper CS, Grover PL (eds): Chemical Carcinogenesis and Mutagenesis II, pp 159-224 Berlin, Springer-Verlag, 1990.
9. Vogelstein B, Fearon ER, Hamilton SR: Genetic alterations during colorectal tumor development. N Engl J Med 319:525-532, 1988.
10. Mao L, Lee JS, Kurie JM, et al: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89(12):857-862, 1997
11. Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12:851-873, 1994.
12. Wattenberg LW: Chemoprevention of cancer. Prev Med 25:44-45, 1996.
13. Wattenberg LW: Prevention, therapy, and basic science and the resolution of the cancer problem Cancer Res 53:5890-5896, 1993.
14. Lippman SM, Lee JS, Lotan R, et al: Biomarkers as intermediate endpoints in Chemoprevention trials. J Natl Cancer Inst 82:555-560, 1990.
15. Greenwald P: Preventive clinical trials. Ann N Y Acad Sci 768:129-140, 1995.
16. O'Shaughnessy JA: Chemoprevention of breast cancer. JAMA 275:1349-1353, 1996.
17. Kelloff GJ, Boone CW, Crowell JA, et al: Chemopreventive drug development. Perspectives and progress Cancer Epidemiol Biomarkers Prev 3:85-98, 1994.
18. Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: Progress and promise. J Natl Cancer lust 90:1514-1528, 1998.
19. Buring JE, Hennekens CH: Intervention studies, in Schottenfeld D, Fraumeni JF, Jr (eds): Cancer Epidemiology and Prevention, pp 1422-1432. New York, Oxford University Press, 1996.
20. Krinsky NI: Actions of carotenoids in biologic systems. Ann Rev Nutr 13:561, 1993.
21. Peto R, Doll R, Buckley JD, et al: Can dietary β-carotene materially reduce human cancer rates? Nature 290:201-209, 1981.
22. Floyd RA: Role of free radicals in carcinogenesis and brain ischemia. FASEB J 4:2587, 1990.
23. Omenn GS: Chemoprevention of lung cancer: The rise and demise of beta-carotene. Annu Rev Public Health 19:73-99, 1998.
24. Burton GW, Ingold KU: Beta-carotene: An unusual type of lipid antioxidant. Science 224:569-573, 1984.
25. Palan PR, Mikhail MS, Goldberg GL, et al: Plasma levels of β-carotene, lycopene, anthoxanthin, retinol, and α- and τ-tocopherol in cervical intraepithelial neoplasia and cervical cancer. Clin Cancer Res 2:181-185, 1996.
26. Levy J, Bosin E, Feldman B, et al: Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 24:257-266, 1995
27. Murakoshi M, Nishino H, Satomi Y, et al: Potent preventive action of α-carotene against carcinogenesis: Spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by α-carotene than by β-carotene Cancer Res 52:6583-6587, 1992.
28. Schrauzer GN. Selenium Mechanistic aspects of anticarcinogenic action. Biol Trace Elem Res 33: 51-62, 1992.
29. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (part 1). Cancer Treat Rep 71(4): 391-405, 1987.
30. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (part 2). Cancer Treat Rep 71(5): 493-515, 1987.
31. Davies P, Lippman SM: Biologic basis of retinoid pharmacology: Implications for cancer prevention and therapy. Adv Oncol 12:2-10, 1996
32. Hofmann C, Eichere C: Retinoids in development, in Spurn MB, Roberts AB, Goodman DE (eds): The Retinoids: Biology, Chemistry, and Medicine, 2nd ed, pp 387-442. New York, Raven Press, 1994.
33. Manglesdorf DJ, Umesono K, Evans RM: The retinoid receptors, in Sporn MB, Roberts AB, Goodman DS (eds). The Retinoids: Biology, Chemistry, and Medicine, 2nd ed, pp 319-349. New York, Raven Press, 1994
34. Mangelsdorf DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: The second decade. Cell 83:835-839, 1995.
35. Sporn MB, Roberts AB, Goodman DS (eds): The Retinoids, 2nd ed. New York. Raven Press, 1994
36. Smith MA, Parkinson DR, Cheson BD, et al: Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992.
37. Dabal R, Boyer CM, Berchuck A, et al: Synergistic inhibition of ovarian cancer cell proliferation by TGF-β and retinoic acid derivatives. Proc Annu Meet Am Assoc Cancer Res 36:A3782, 1995.
38. Hong WK, Sporn MB: Recent advances in chemoprevention of cancer Science 278:1073-1077, 1997.
39. Potischman N: Nutritional epidemiology of cervical neoplasia. J Nutr 123:424-429, 1993.
40. Kvale G, Bjelke E, Cart JJ: Dietary habits and lung cancer risk Int J Cancer 15:397-405, 1983.
41. Hunter DJ, Stampfer MJ, Colditz GA, et al: A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 329:234-240, 1993.
42. Hirayama T: A large scale cohort study on cancer risk by diet-with special reference to the risk reducing effects of green-yellow vegetable consumption, in Hayashi Y (ed): Diet Nutrition and Cancer, pp 41-53. Tokyo, Japan Scientific Societies Press, 1986.
43. Clinton SK, Emenhiser C, Giovannucci EL, et al: Cis-trans isomers of lycopene in the human prostate: A role in cancer prevention? FASEB J 9:A42, 1995.
44. Eichholzer M, Sthelin HE, Gey KF, et al: Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up study of the prospective Basel study. Int J Cancer 66:145-150, 1996
45. Clark LC, Cantor KP, Allaway WH: Selenium in forage crops and cancer mortality in US counties. Arch Environ Health 46:37-42, 1991.
46. Garland NI, Morris JS, Stampier MJ, et al: Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87:497-505, 1995.
47. Vinceti M, Rothman KJ, Bergomi M, et al: Excess melanoma incidence in a cohort exposed to high levels of environmental selenium. Cancer Epidemiol Biomarkers Prev 7:853-856, 1998.
48. Hennekens CH, Buring JE, Manson JE, et al: Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145-1149, 1996.
49. Clark LC, Combs GF, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276:1957-1963, 1996.
50. Taylor PR, Albanes D: Selenium, vitamin E, and prostate cancer - ready for prime time? J Natl Cancer Inst 90:1184-1185, 1998.
51. Yoshizawa K, Willett WC, Morris SJ, et al: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90:1219-1224, 1998.
52. Heinonen OP, Albanes D, Virtamo J, et al: Prostate cancer and supplementation with α-tocopherol and β-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440-446, 1998.
53. Lotan R, Xu X-C, Lippman SM, et al: Suppression of retinoic acid receptor β in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332:1405-1410, 1995.
54. Mao L, Lee JS, Fran YH, et al: Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and its value in cancer risk assessment. Nature Med 2:682-685, 1996.
55. Hong WK, Lippman SM, Hittelman WN, et al: Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic. Clin Cancer Res 1:677-686, 1995.
56. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993.
57. Papadimitrakopoulou VA, Hong WK, Lee JS, et al: Low-dose isotretinoin vs β-carotene to prevent oral carcinogenesis: Long-term follow up. J Natl Cancer Inst 89:49-50, 1997.
58. Stich HF, Rosin MP, Homby P, et al: Remission of oral leukoplakias and micronuclei in tobacco/betel chewers treated with β-carotene and with β-carotene plus vitamin A. Int J Cancer 42:195-199, 1988.
59. Benner SE, Winn RJ, Lippman SM, et al: Regression of oral leukoplakia with α-tocopherol: A community clinical oncology program chemoprevention study. J Natl Cancer Inst 85:44-47, 1993.
60. Zaridze D, Evstifeeva T, Boyle P: Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Ann Epidemiol 3:225-234, 1993.
61. Hong WK, Endicott J, Itri LN, et al: 13-Cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986.
62. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993.
63. Han J, Jiao L, Lu Y, et al: Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 4:153-160, 1990.
64. Chiesa F, Tradati N, Marazza M, et al: 4HPR in chemoprevention of oral leukoplakia. J Cell Biochem 17F(suppl):255-261, 1993.
65. Gouveia J, Mathe G, Hercend T, et al: Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet 1:710-712, 1983.
66. Arnold AM, Browman GP, Levine MN, et al: The effect of synthetic retinoid etretinate on sputum cytology: Results from a randomized trial. Br J Cancer 65:737-743, 1992.
67. Lee JS, Lippman SM, Benner SE, et al: A randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 12:937-945, 1994.
68. Van Poppel G, Kok FJ, Hermus RJ: β-Carotene supplementation in smokers reduces the frequency of micronuclei in sputum. Br J Cancer 66:1164-1168, 1992.
69. Van Poppel G, Poulsen H, Loft S, et al: No influence of β-carotene on oxidative DNA damage in male smokers. J Natl Cancer Inst 87:310-311, 1995.
70. McLarty JW, Holiday DB, Girard WM, et al: β-carotene, vitamin A, and lung cancer chemoprevention: Results of an intermediate endpoint study. Am J Clin Nutrition 62(suppl):1431s-1438s, 1995.
71. Pastorino U, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with high dose vitamin A. J Clin Oncol 11:1216-1222, 1993.
72. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous carcinoma of the head and neck. N Engl J Med 323:795-801, 1990.
73. Benner SE, Pajak TF, Lippman SM, et al: Prevention of second primary tumors with 13cRA in squamous cell carcinoma of the head and neck: Long term follow-up. J Natl Cancer Inst 86:140-141, 1994.
74. Bolla M, Lefur R, Ton Van J, et al: Prevention of second primary tumors with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicenter double blind randomized study. Eur J Cancer 30A:767-772, 1994
75. Benner SE, Pajak TF, Lippman SM, et al: Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck, cancer. J Natl Cancer Inst 86:1799-1801, 1994.
76. Lippman SM, Hong WK: Not yet standard: Retinoids vs second primary tumors. J Clin Oncol 11:1204-1207, 1993
77. Lippman SM, Lee JJ, Karp DD, et al: Phase III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage I non-small-cell lung cancer (NSCLC): Interim report of NCI #191-0001 (abstract). Proc Am Soc Clin Oncol 17:456a, 1998.
78. Wu XF, Hu Y, Lippman SM: Upper aero-digestive tract cancers, in Neugut AI, Meadows AT, Robinson E (eds): Multiple Primary Cancers: Incidence, Etiology, Diagnosis and Prevention, Baltimore, Maryland, Williams & Wilkins, 1998 (in press).
79. Van Zandwijk N: N-acetylcysteine and glutathione: Antioxidant and chemopreventive properties, with special reference to lung cancer. J Cell Biochem 22(suppl):24-32, 1995.
80. Blot WJ, Li J-Y, Taylor PR, et al: Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence and disease specific mortality in the general population. J Natl Cancer Inst 85:1483-1492, 1993.
81. Li J-Y, Taylor PR, Li B, et al: Nutrition intervention trials in Linxian. China: Multiple vitamin/mineral supplementation cancer incidence and disease specific among adults with esophageal dysplasia. J Natl Cancer Inst 85:1492-1498, 1993.
82. The Alpha-Tocopherol/β-Carotene Cancer Prevention Study Group: The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancer in male smokers. N Engl J Med 330:1029-1035, 1994.
83. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996.
84. Omenn GS, Goodman GE, Thomquist MD, et al: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88:1550-1559, 1996.
85. Kraemer KH, DiGiovanna JJ, Moshell AN, et al: Prevention of skin cancer in xerodenna pigmentosum with oral isotretinoin. N Engl J Med 318:1633-1637, 1988.
86. Tangrea JA, Edwards BK, Taylor PR, et al: Long-term therapy with low dose isotretinoin for prevention of basal cell carcinoma: A multi-center clinical trial: Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 84:328-332, 1992.
87. Moon TE, Levine N, Cartmel B, et al: Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 6:949-956, 1997.
88. Levine N, Moon TE, Cartmel B, et al: Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 6 957-961, 1997.
89. Greenberg ER, Baron JA, Stukel TA, et al: A clinical trial of β-carotene to prevent basal cell and squamous cell carcinomas of the skin. N Engl J Med 323:789-795, 1990.
90. Colditz GA: Selenium and cancer prevention- Promising results indicate further trials required. JAMA 276:1984-1985, 1996.
91. Mitchell ME, Hittleman WN, Hong WK, et al: The natural history of cervical intraepithelial neoplasia: An argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 3:619-626, 1994
92. Wright TC, Kurman RJ, Ferenczy A: Pre-cancerous lesions of the ceivix, in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract, 4th ed., pp 229-277. New York, Springer-Verlag, 1994
93. De Vet HC, Knipschild PG, Willebrands D, et al: The effect of β-carotene on the regression and progression of cervical dysplasia: A clinical experiment. J Clinical Epidemiol 44:273-283, 1991.
94. Meyskens FL, Manetta A: Prevention of cervical intraepithelial neoplasia and cancer. Am J Clin Nutr 62(suppl):1417s-1419s, 1995.
95. Butterworth CE, Hatch KD, Soong SJ, et al: Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial. Am J Obstet Gynecol 166:803, 1992
96. Childers JM, Chu J, Voight LF, et al: Chemoprevention of cervical cancer with folic acid: A phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 4:155-159, 1995.
97. Romney SL, Dywer A, Slagle S, et al: Chemoprevention of cervix cancer: Phase I-II: A feasibility study involving the topical vaginal administration of retinyl acetate gel. Gynecol Oncol 20:109, 1985.
98. Surwit EA, Graham V, Droegmueller W, et al: Evaluation of topically applied trans retino ic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 143:821, 1982.
99. Meyskens FL, Graham V, Chvapil M, et al: A phase I trial of β-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst 71:921, 1983
100. Weiner SA, Surwit EA, Graham VE, et al: A phase I trial of topically applied trans retinoic acid in cervical dysplasia - clinical efficacy. Invest New Drugs 4:241, 1986.
101. Meyskens FL, Surwit EA, Moon TE, et al: Enhancement of regression of cervical intraepithelial neopiasia II with topically applied all-trans retinoic acid: A randomized trial. J Natl Cancer Inst 86:539, 1994.
102. Mitchell ME, Tortolero-Luna G, Lee JJ, et al: Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4:303-310, 1998.
103. Torrisi R, Parodi S, Fontana V: Effect of fenretinide on IGF-1 and IGFBP-3 in early breast cancer patients. Int J Cancer 76(6):787-790, 1998
104. Giovannucci E, Stampher MF, Colditz GA, et al: Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study Ann Intern Med 129:517-524, 1998.
105. Greenberg ER, Baron JA, Tostenson TD, et al: A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 331:141-147, 1994.
106. MacLennan R, Macrae F, Bain C, et al: Randomised trial of intake of fat, fiber, and β-carotene to prevent colorectal adenomas. J Natl Cancer Inst 87:1760-1766, 1995.
107. Holmang S, Hedelin H, Anderstrom C, et al: The relationship among multiple recurrences, progression, and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153:1823-1827, 1995.
108. Lamm DL, Torti FM: Bladder cancer. 1996 CA Cancer J Clin 46:93-112, 1996.
109. Kelloff GJ, Boone CW, Malone WF, et al: Development of chemopreventive agents for bladder cancer. J Cell Biochem 161(suppl):1-12. 1992.
110. Lamm DL, Riggs DR, Shriver JS, et al: Megadose vitamins in bladder cancer: A double-blind clinical trial. J Urol 151:21-26, 1994.
111. Muto Y, Moriwaki H, Ninomiya M, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma: Hepatoma Prevention Study Group. N Engl Med 334:1561-1567, 1996